Elsevier

Atherosclerosis

Volume 314, December 2020, Pages 58-62
Atherosclerosis

Review article
Endothelial dysfunction in COVID-19: Current findings and therapeutic implications

https://doi.org/10.1016/j.atherosclerosis.2020.10.014Get rights and content
Under a Creative Commons license
open access

Highlights

  • New evidence implicates endothelial dysfunction in the pathophysiology of COVID-19.

  • It may explain complications such as multi-organ damage or thrombotic events.

  • Targeted interventions such as RAS inhibitors or statins may improve outcomes.

  • Studies on interventions that affect endothelial dysfunction are underway in COVID-19.

Abstract

Coronavirus disease 2019 (COVID-19) increases the risk of several non-pulmonary complications such as acute myocardial injury, renal failure or thromboembolic events. A possible unifying explanation for these phenomena may be the presence of profound endothelial dysfunction and injury. This review provides an overview on the association of endothelial dysfunction with COVID-19 and its therapeutic implications. Endothelial dysfunction is a common feature of the key comorbidities that increase risk for severe COVID-19 such as hypertension, obesity, diabetes mellitus, coronary artery disease or heart failure. Preliminary studies indicate that vascular endothelial cells can be infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and evidence of widespread endothelial injury and inflammation is found in advanced cases of COVID-19. Prior evidence has established the crucial role of endothelial cells in maintaining and regulating vascular homeostasis and blood coagulation. Aggravation of endothelial dysfunction in COVID-19 may therefore impair organ perfusion and cause a procoagulatory state resulting in both macro- and microvascular thrombotic events. Angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and statins are known to improve endothelial dysfunction. Data from smaller observational studies and other viral infections suggests a possible beneficial effect in COVID-19. Other treatments that are currently under investigation for COVID-19 may also act by improving endothelial dysfunction in patients. Focusing therapies on preventing and improving endothelial dysfunction could improve outcomes in COVID-19. Several clinical trials are currently underway to explore this concept.

Keywords

COVID-19
SARS-CoV2
Coronavirus
Endothelial dysfunction
Renin angiotensin system
Statin

Cited by (0)